

Ajanta House Charkop, Kandivli West, Mumbai 400 067 India T +91 22 6606 1000 F +91 22 6606 1200 E info@ajantapharma.com W www.ajantapharma.com

20th May 2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 National Stock Exchange of India Exchange Plaza, 5th Floor, Plot No. C/1, G block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: BSE – AJANTPHARM 532331

Scrip Code: NSE AJANTPHARM EQ

Subject: - Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), 2015

Dear Sir / Madam,

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of Related Party Transactions on a consolidated basis for the half year ended 31st March 2022.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

Gaurang Shah

VP – Legal & Company Secretary

Encl.: a/a

Disclosure of Related Party Transaction for the half year ended 31st March 2022

	Petails of the party (listed /subsidiary) entering int transaction Name		Details of th Name	PAN	Relationship of the	Type of related party transaction (see Note 5 of the Circular)	Value of the related party transaction as approved by the	Value of transaction	In case monie		relates to loans,	inter-corpo nese details al indebted	need to b tran	sits, advances on the disclosed only saction was und	r investi once, d ertaken	nents n uring tl	nade or g he report rporate d	lated party transactior given by the listed ting period when such deposits, advances or
	/subsidiary) entering int transaction	o the			Relationship of the	transaction (see Note 5 of	related party transaction as	transaction			entity/subsidiary. The last of	nese details al indebted	need to b tran	e disclosed only saction was und	once, d ertaken	uring th	he report	ting period when such
	/subsidiary) entering int transaction	o the			Relationship of the	transaction (see Note 5 of	related party transaction as	transaction			In case any financi	al indebted	tran ness is	saction was unc	ertaken	nter-co	rporate d	
	/subsidiary) entering int transaction	o the			Relationship of the	transaction (see Note 5 of	related party transaction as	transaction					ness is			nter-co		eposits, advances or
	/subsidiary) entering int transaction	o the			Relationship of the	transaction (see Note 5 of	related party transaction as	transaction						Details of the	loans, i			leposits, advances or
	/subsidiary) entering int transaction	o the			Relationship of the	transaction (see Note 5 of	related party transaction as	transaction						Details of the	loans, i			leposits, advances or
	/subsidiary) entering int transaction	o the			Relationship of the	transaction (see Note 5 of	related party transaction as	transaction						Details of the	loans, I			deposits, advances or
	transaction		Name	PAN		•	transaction as		either party a	s a result of	incurred to make o	r give laans	intor			invest		
1 Aian		PAN	Name	PAN		the Circular)											iments	
1 Aian	Name	PAN	Name	PAN			approved by the	during the reporting	the transaction (see Note 1)		corporate depos							
1 Aian	Name	PAN	Name	PAN							invest							
1 Aian	Name	PAN	Name	PAN			audit committee	period (see										
1 Aian							(see Note 6a of	Note 6b)	Opening	Closing	Nature of	Cost (see	Tenure		Inter 1	enur S		Purpose for which the
1 Aian					counterparty with the listed		the Circular)		Balance	Balance	indebtedness (loan/ issuance of debt/ any other etc.)	Note 7 of		advance/ inter	est	е	d/ fu	unds will be utilised b
1 Aian					entity or its subsidiary							the		corporate	Rate	u	ınsecu t	the ultimate recipient
1 Aian					1							Circular)		deposit/	(%)		red	of funds (end-usage)
1 Aian														investment				
1 Aian																		
1 Aian																		
1 Aian																		
	nta Pharma Limited		Aayush M. Agrawal		Promoter	Dividend paid	-	0.02	-	-								-
2 Ajan	nta Pharma Limited		Aayush M. Agrawal, trustee Aayush		Promoter	Dividend paid	-	11.80	-	-								
			Agrawal Trust			·												
3 Ajani	nta Pharma Limited		Aayush M. Agrawal, Trustee Aayush		Promoter	Buyback of Equity Shares	-	41.21	-	-								
-			Agrawal Trust															
4 Ajani	nta Pharma Limited		Ajanta Foundation		Company is able to exercise	Corporate Social	0.15	0.15	-	-								
ľ			•		significant control over this	Responsibility expense												
					entity	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,												
4 Aian	nta Pharma Limited		M/s. Al Packaging		Relative of Chairman	Purchase of Goods	7.55	4.04	-	_								
,	nta Pharma Limited		M/s. Al Packaging		Relative of Chairman	Trade Payables	-		0.56	0.95								
	nta Pharma Limited		Ajanta Pharma (Mauritius) Ltd		Subsidiary	Sale of Goods	-	20.18	-	-								
	nta Pharma Limited		Ajanta Pharma (Mauritius) Ltd		Subsidiary	Purchase of Capital Goods	-	0.17	-	_								
, ,,,,,,,	ita i nama Emilea		rijania i narma (maaritias) zta		Substatut y	i di chase or capital occas		0.17										
8 Aian	nta Pharma Limited		Ajanta Pharma (Mauritius) Ltd		Subsidiary	Trade Receivables	-		42.07	42.30								
	nta Pharma Limited		Ajanta Pharma (Mauritius) Ltd		Subsidiary	Trade Payables	-		-	0.17								
	nta Pharma Limited		Ajanta Pharma (Mauritius) Ltd		Subsidiary	Investment in equity	_		9.44	9.44								
	nta Pharma Limited		Ajanta Pharma Limited Group Gratuity		Company is able to exercise	Contribution to	-	0.37	-	-								
- 1, Juli	ita i nama Emilea		Trust		significant control over this	post employment benefit		0.57										
					entity	plans												
12 Aian	nta Pharma Limited		Ajanta Pharma Nigeria Ltd		Subsidiary	Reimbursement of	-	0.25	-	-								
'			,		,	expenses												
13 Ajani	nta Pharma Limited		Ajanta Pharma Nigeria Ltd		Subsidiary	Advance given	_		-	0.07								
- ,	nta Pharma Limited		Ajanta Pharma Philippines Inc.		Subsidiary	Sale of Goods	_	98.60	-	- 0.07								
	nta Pharma Limited		Ajanta Pharma Philippines Inc.		Subsidiary	Trade Receivables	-	30.00	6.46	41.75								
	nta Pharma Limited	1	Ajanta Pharma Philippines Inc.	1	Subsidiary	Investment in equity	_		1.38	1.38					1 1	-+		
	nta Pharma Limited	<u> </u>	Ajanta Pharma USA Inc.	1	Subsidiary	Sale of Goods	-	242.42	1.36	1.30								
	nta Pharma Limited	<u> </u>	Ajanta Pharma USA Inc.	1	Subsidiary	Other income	-	0.56	-	-								
	nta Pharma Limited	<u> </u>	Ajanta Pharma USA Inc.	+	Subsidiary	Trade Receivables	-	0.36	561.43	661.68					\vdash	-+		
	nta Pharma Limited	 	Ajanta Pharma USA Inc.	+	Subsidiary	Other receivables	-		0.96	0.44				 	 	-+		
	nta Pharma Limited	1	Ajanta Pharma USA Inc.	1	,		-		7.07	7.07					 		+	
	nta Pharma Limited	-	Ajanta Pharma USA Inc. Ajanta Pharma USA Inc.	+	Subsidiary	Investment in equity			74.23						 			
		-	,	1	Subsidiary Chief Financial Officer 8 KMD	Corporate Guarantee	-	0.74	74.23	-					-			
23 Ajani	nta Pharma Limited		Arvind Agrawal		Chief Financial Officer & KMP	Short Term Employee	-	0.74	-	-								
24 4:		1	A	1	01: (5:	benefits		0.00							├			
24 Ajan	nta Pharma Limited		Arvind Agrawal		Chief Financial Officer & KMP	Post-employment benefits	-	0.00	-	-	l	l		1	1 1			

											relates to loans	, inter-corpo	orate depo	Rs in Crore issactions - applicable only in case the related party transaction issits, advances or investments made or given by the listed be disclosed only once, during the reporting period when such saction was undertaken.						
S. No	o. Details of the party (listed entity /subsidiary) entering into the transaction			e counterparty			Value of the related party transaction as approved by the audit committee	arty transaction on as during the by the reporting nittee period (see	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financ incurred to make corporate depo invest					deposits, advances or				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary		(see Note 6a of the Circular)	Note 6b)	Opening Balance	Closing Balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Cost (see Note 7 of the Circular)	Tenure	Nature (loan/ advance/ inter corporate deposit/ investment		Tenur e		Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)		
25	Ajanta Pharma Limited		Arvind Agrawal		Chief Financial Officer & KMP	Dividend paid	-	0.02	-	-										
26	Ajanta Pharma Limited		Arvind Agrawal		Chief Financial Officer & KMP	Buyback of Equity Shares	-	0.13	-	-										
27	Ajanta Pharma Limited		Chandrakant M. Khetan		Independent Director	Sitting fees paid	-	0.03	-	-										
28	Ajanta Pharma Limited		Chandrakant M. Khetan		Independent Director	Commission to Directors	-	0.02		-										
29	Ajanta Pharma Limited		Chandrakant M. Khetan		Independent Director	Dividend paid	-	0.00	-	-										
30	Ajanta Pharma Limited		Chandrakant M. Khetan		Independent Director	Commission payable	-		0.02	0.04										
31	Ajanta Pharma Limited		Dr. Anjana Grewal		Independent Director	Sitting fees paid	-	0.02	-	-										
32	Ajanta Pharma Limited		Dr. Anjana Grewal		Independent Director	Commission to Directors	-	0.01	-	-										
33	Ajanta Pharma Limited		Dr. Anjana Grewal		Independent Director	Commission payable	-		0.01	0.02										
34	Ajanta Pharma Limited		Gabs Investments Pvt Ltd		Promoter	Dividend paid	-	7.97	-	-										
35	Ajanta Pharma Limited		Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal		Promoter	Dividend paid	-	2.23	-	-										
36	Ajanta Pharma Limited		Ganga Exports being represented by Yogesh M. Agrawal, Rajesh M. Agrawal and Ravi P. Agrawal		Promoter	Buyback of Equity Shares	-	11.34	-	-										
37	Ajanta Pharma Limited		Gaurang Shah		Company Secretary & KMP	Short Term Employee benefits	-	0.38	-	-										
38	Ajanta Pharma Limited		Gaurang Shah		Company Secretary & KMP	Post-employment benefits	-	0.00	-	-										
39	Ajanta Pharma Limited		Gaurang Shah		Company Secretary & KMP	Dividend paid	-	0.00	-	-										
40	Ajanta Pharma Limited		Gaurang Shah		Company Secretary & KMP	Buyback of Equity Shares	-	0.00	-	-										
41	Ajanta Pharma Limited		K. H. Viswanathan		Independent Director	Sitting fees paid	-	0.04	-	-										
42	Ajanta Pharma Limited		K. H. Viswanathan		Independent Director	Commission to Directors	-	0.01	-	-										
43	Ajanta Pharma Limited	1	K. H. Viswanathan		Independent Director	Commission payable	-	1	0.01	0.02	1		<u> </u>	1	t					
	Ajanta Pharma Limited		Madhusudan B. Agrawal		Executive Vice-Chairman	Short Term Employee	-	1.71		-							İ			
						benefits														

Disclosure of Related Party Transaction for the half year ended 31st March 2022

											Rs in Additional disclosure of related party transactions - applicable only in case the related party trans relates to loans, inter-corporate deposits, advances or investments made or given by the liste entity/subsidiary. These details need to be disclosed only once, during the reporting period wher										
											chary, substantity.	nese details		saction was und			inc repe	Ting period when such			
S. No.	No. Details of the party (listed entity /subsidiary) entering into the transaction		Details of the	ne counter	party	transaction (see Note 5 of the Circular) rela tran appro	transaction as approved by the	Value of transaction during the reporting period (see	the transaction (see Note 1)		In case any financ incurred to make o corporate depos invest										
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary		(see Note 6a of the Circular)	Note 6b)		Closing Balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7 of the Circular)	Tenure	Nature (loan/ advance/ inter corporate deposit/ investment		e	Secure d/ unsecu red	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)			
45	Ajanta Pharma Limited		Madhusudan B. Agrawal		Executive Vice-Chairman	Post-employment benefits	-	0.03	-	-						\dashv					
46	Ajanta Pharma Limited		Mamta and Madhusudan Agrawal Memorial Foundation		Promoter group is able to exercise significant control over this entity	Corporate Social Responsibility expense	0.19	0.19	-	-											
47	Ajanta Pharma Limited		Manisha Yogesh Agrawal Foundation		Promoter group is able to exercise significant control over this entity	Donation expense	0.15	0.15	-	-											
48	Ajanta Pharma Limited		Mannalal B. Agrawal		Non Executive Director - Chairman	Sitting fees paid	-	0.04	-	-											
49	Ajanta Pharma Limited		Prabhakar Dalal		Independent Director	Sitting fees paid	-	0.03	-	-											
50	Ajanta Pharma Limited		Prabhakar Dalal		Independent Director	Commission to Directors	-	0.01	-	-											
51	Ajanta Pharma Limited		Prabhakar Dalal		Independent Director	Commission payable	-		0.01	0.02											
	Ajanta Pharma Limited		Rajesh M. Agrawal		Joint Managing Director & KMP	Short Term Employee benefits	-	5.53	-	-											
53	Ajanta Pharma Limited		Rajesh M. Agrawal		Joint Managing Director & KMP	Post-employment benefits	-	0.03	-	-											
54	Ajanta Pharma Limited		Rajesh M. Agrawal		Joint Managing Director & KMP	Commission to Directors	-	3.61	-	-											
55	Ajanta Pharma Limited		Rajesh M. Agrawal		Joint Managing Director & KMP	Commission payable	-		1.64	5.25											
56	Ajanta Pharma Limited		Rajesh M. Agrawal, trustee Rajesh Agrawal Trust		Promoter	Dividend paid	-	11.91	-	-											
57	Ajanta Pharma Limited		Rajesh M. Agrawal, Trustee Rajesh Agrawal Trust		Promoter	Buyback of Equity Shares	-	39.04	-	-											
58	Ajanta Pharma Limited	İ	Ravi P. Agrawal		Promoter	Dividend paid	-	0.18	-	-						$\neg \uparrow$					
	Ajanta Pharma Limited		Ravi P. Agrawal, trustee Ravi Agrawal Trust		Promoter	Dividend paid	-	11.81	-	-											
60	Ajanta Pharma Limited		Ravi P. Agrawal, Trustee Ravi Agrawal Trust		Promoter	Buyback of Equity Shares	-	40.01	-	-											

Ajanta Pharma Limited

Disclosure of Related Party Transaction for the half year ended 31st March 2022

Rs in Crore

S. No.	. Details of the party (listed	d entity	Details of th	e counter	party	Type of related party	Value of the	Value of	In case monie	es are due to	Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. to In case any financial indebtedness is Details of the loans, inter-corporate deposits, advances or										
	/subsidiary) entering into the transaction			•	transaction (see Note 5 of the Circular)	related party transaction as approved by the audit committee	transaction during the reporting period (see	either party as a result of the transaction (see Note 1)		incurred to make o corporate depos invest	investments										
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary		(see Note 6a of the Circular)	Note 6b)	Opening Balance	Closing Balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7 of the Circular)	Tenure	advance/ inter-		e d/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)				
61	Ajanta Pharma Limited		Seth Bhagwandas Agarwal Charitable Trust		Promoter group is able to exercise significant control over this entity	Donation expense	0.35	0.15	-	-											
62	Ajanta Pharma Limited		Tanya Agrawal		Daughter of Managing Director	Short Term Employee benefits	-	0.04	-	-											
63	Ajanta Pharma Limited		Tanya Agrawal		Daughter of Managing Director	Post-employment benefits	-	0.00	-	-											
64	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Short Term Employee benefits	-	5.53	-	-											
65	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Post-employment benefits	-	0.04	-	-											
66	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Commission to Directors	-	3.61	-	-											
67	Ajanta Pharma Limited		Yogesh M. Agrawal		Managing Director & KMP	Commission payable	-		1.64	5.25											
68	Ajanta Pharma Limited		Yogesh M. Agrawal, trustee Yogesh Agrawal Trust		Promoter	Dividend paid	-	11.91	-	-											
69	Ajanta Pharma Limited		Yogesh M. Agrawal, Trustee Yogesh Agrawal Trust		Promoter	Buyback of Equity Shares	-	39.04	-	-											

Note: Amount approved by Audit Committee is for the entire financial year